Trifork Group (TRIFOR) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
5 May, 2026Executive summary
Achieved 8% organic growth and 27% adjusted EBITDA growth year-over-year in Q1 2026, driven by a product-led strategy, cost control, and strong public sector wins.
Product business now represents 45% of total revenue, up from 40% last year, with public sector revenue also at 45% and a 78% public tender win rate.
Strategic focus on digital health, financial services, public, aviation, and energy sectors, with new leadership and international expansion in Germany and Canada.
Significant new contracts include a 4-year deal with Denmark's National Agency for IT and Learning and digital health contracts in Germany and Canada.
Strategic review of Labs portfolio ongoing, with discussions about structured exit opportunities.
Financial highlights
Q1 2026 revenue was EUR 56.1M, down 2.4% year-over-year due to hardware sales phasing, but organic growth excluding hardware was 8.3%.
Adjusted EBITDA margin improved to 15.5%, up 3.6 percentage points year-over-year, with adjusted EBITDA at EUR 8.7M.
Product segment delivered a 27% margin and 28% organic revenue growth (excluding hardware), with 135% year-over-year EBITDA growth.
Services segment grew 1% organically, with a 14% margin and a 5% decline in EBITDA year-over-year.
Q1 cash conversion was 89%, with slower conversion due to delayed payment on a large deal and EUR 3.5M CapEx buildup for sovereign data centers.
Outlook and guidance
Full-year 2026 guidance maintained: revenue EUR 230–240M, organic growth 7–11%, and adjusted EBITDA EUR 35–40M (15–17% margin, 16–33% growth).
Margins expected to improve as AI-related pricing models are implemented and product scale increases.
Hardware sales expected to remain at least at 2025 levels.
Strategic review of Labs portfolio ongoing, with conclusions expected in the first half of the year.
Latest events from Trifork Group
- Q1 2026 saw 27% adjusted EBITDA growth and margin expansion, with 2026 guidance reaffirmed.TRIFOR
Q1 20265 May 2026 - Record 2025 revenue and margin gains, with strong product and cash flow growth outlook.TRIFOR
Q4 20258 Apr 2026 - Revenue up 7.3% to EUR 220.9M, strong product growth, margin recovery, and robust outlook.TRIFOR
Q4 202527 Feb 2026 - Revenue and margins fell, but public sector momentum and Labs gains support future outlook.TRIFOR
Q2 202423 Jan 2026 - Product-driven growth, innovation in AI and digital health, and strong 2025 financial targets.TRIFOR
Danske Bank Winter Seminar presentation19 Jan 2026 - Revenue and margins fell in 2024, triggering cost cuts and growth in US and public sector Denmark.TRIFOR
Q3 202417 Jan 2026 - Q2 2025 revenue up 5.1%, with product focus and digital health wins fueling future growth.TRIFOR
Investor presentation16 Jan 2026 - Product-driven growth, innovation in AI, and strong 2025 financial targets define the outlook.TRIFOR
Investor presentation16 Jan 2026 - Product-led transformation, robust 2025 outlook, and strong Labs investment performance.TRIFOR
SEB Nordic Seminar presentation16 Jan 2026